(KMA) and Lambda Myeloma Antigen (LMA), have been identified on the surface of human blood cancer and autoimmune cells. These targets are highly specific to abnormal B-cells and have been identified in blood cancers such as multiple myeloma (MM), lymphoma and Waldenstroms macroglobulinemia.

Our program will rationally review and pursue opportunities that will deliver a positive proof of the clinical and financial viability of our assets. These opportunities include:

validation of antibodies and CAR-T cells;

proof of concept for both Kappa and Lambda antigens; and

a good understanding of their clinical utility in treating the selected patient populations

In pursuing these projects we wish to deliver significant and risk mitigated medium term returns to our investors.